Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + bortezomib + abatacept
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen of three drugs—cyclophosphamide, bortezomib, and abatacept—used primarily for the prevention of graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Cyclophosphamide is an alkylating agent that suppresses immune responses by cross-linking DNA. Bortezomib is a proteasome inhibitor that disrupts protein degradation pathways in cells, leading to apoptosis of activated immune cells. Abatacept is a selective co-stimulation modulator that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells and preventing their interaction with CD28 on T-cells. This combination aims to reduce the incidence and severity of both acute and chronic GvHD while maintaining engraftment and minimizing relapse risk in patients with hematologic malignancies undergoing allo-HSCT[1][2][8].
- Other names
- cyclophosphamide + bortezomib + abatacept
02
Targets
CD86 (T-lymphocyte activation antigen CD86)CD80 (T-lymphocyte activation antigen CD80)DNAPSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on cyclophosphamide + bortezomib + abatacept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + bortezomib + abatacept.